Crestor vs Lisinopril: Side-Effect Profile Head-to-Head

Why These Two Drugs Get Compared

Rosuvastatin and lisinopril sit in different pharmacologic classes, yet they land on the same medication list for millions of patients with overlapping cardiometabolic risk. A person with hypertension and dyslipidemia may take both simultaneously. The question patients ask most often is not "which one should I take instead of the other" but rather "which one is causing my side effects?"

Rosuvastatin lowers LDL cholesterol by inhibiting the enzyme HMG-CoA reductase in the liver. The JUPITER trial (N=17,802) demonstrated a 44% reduction in major cardiovascular events among adults with LDL <130 mg/dL but elevated high-sensitivity C-reactive protein (hsCRP), establishing rosuvastatin's role beyond traditional lipid targets [1]. Lisinopril lowers blood pressure by blocking angiotensin-converting enzyme, reducing the production of angiotensin II. The ALLHAT trial (N=33,357) tested lisinopril against chlorthalidone and amlodipine for hypertension management, finding equivalent coronary heart disease outcomes but a worse stroke profile for lisinopril relative to the thiazide diuretic [2].

Because no randomized controlled trial has directly compared rosuvastatin against lisinopril, this analysis synthesizes adverse-event data from each drug's key trials, FDA prescribing information, and post-marketing surveillance.

Muscle-Related Side Effects: The Statin Burden

Myalgia is the side effect most associated with statins, and rosuvastatin is no exception. In clinical trials, muscle complaints appeared in roughly 5-10% of patients on rosuvastatin, though the true real-world rate may differ based on the nocebo effect, which has been well-documented in statin research.

The SAMSON trial (N=60) used an n-of-1 design and found that 90% of symptom burden attributed to statins was also present during placebo periods [3]. That does not mean statin myalgia is imaginary. It means many patients who stop their statin due to muscle pain might tolerate the drug if re-challenged under blinded conditions. True statin-associated muscle symptoms (SAMS) appear to affect roughly 5-7% of users after nocebo effects are accounted for, according to a 2022 Lancet review analyzing individual-participant data from over 150,000 patients across 23 trials [4].

Serious muscle injury, rhabdomyolysis, is exceedingly rare with rosuvastatin: fewer than 1 in 10,000 patient-years in post-marketing data reported to the FDA Adverse Event Reporting System. Rosuvastatin carries the lowest lipophilicity among statins, meaning it has reduced muscle-cell penetration compared to simvastatin or atorvastatin. The 2019 ACC/AHA guideline on primary prevention recommends rosuvastatin as one of two preferred high-intensity statins partly because of its favorable muscle-safety profile [5].

Lisinopril, by contrast, causes virtually no muscle complaints. If a patient on both drugs reports myalgia, the statin is the likely culprit.

The ACE Inhibitor Cough

Dry, persistent, nonproductive cough is the signature nuisance of every ACE inhibitor, lisinopril included. Estimates range from 5% to 15% depending on the population studied. The mechanism involves accumulation of bradykinin and substance P in the bronchial mucosa, which ACE normally degrades.

A meta-analysis published in the Annals of Internal Medicine estimated the pooled incidence of ACE inhibitor cough at 9.9% [6]. Women are affected roughly twice as often as men. East Asian populations also show higher susceptibility, with some studies reporting rates above 20%, likely due to polymorphisms in the bradykinin B2 receptor gene. Cough typically starts within 1 to 6 months of initiation and resolves within 1 to 4 weeks after discontinuation.

Rosuvastatin does not cause cough. So when a patient taking both drugs develops a new dry cough, stopping lisinopril (or switching to an angiotensin receptor blocker) is the standard next step rather than adjusting the statin.

Angioedema Risk with Lisinopril

Angioedema is rare but demands attention. It presents as rapid swelling of the face, lips, tongue, or airway and can be life-threatening. The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial (N=25,302) documented angioedema in 0.68% of patients on the ACE inhibitor enalapril, with Black patients facing a 3-fold higher incidence compared to non-Black patients [7].

Lisinopril-specific post-marketing data from the FDA prescribing label confirms a comparable rate. Angioedema can occur at any point during treatment, from the first dose to years later. The American College of Allergy, Asthma, and Immunology recommends that any patient who experiences ACE inhibitor-induced angioedema be permanently switched to a different antihypertensive class rather than re-challenged [8].

Rosuvastatin has no meaningful angioedema signal. Allergic reactions to statins exist but are uncommon and typically mild (urticaria, rash), appearing in fewer than 1% of trial participants [1].

Metabolic Effects: Diabetes Risk with Rosuvastatin

JUPITER revealed an unexpected finding: a 25% relative increase in physician-reported diabetes among participants randomized to rosuvastatin 20 mg vs. placebo (3.0% vs. 2.4% over a median 1.9 years) [1]. A subsequent meta-analysis in The Lancet (13 statin trials, N=91,140) confirmed a 9% proportional increase in incident diabetes across all statins [9]. Rosuvastatin and atorvastatin, the two high-intensity statins, appeared to carry a slightly greater risk than moderate-intensity agents.

The clinical interpretation matters more than the headline number. The Cholesterol Treatment Trialists' Collaboration showed that for every 255 patients treated with a statin for 4 years, approximately 1 extra case of diabetes would be expected, while 5.4 major vascular events would be prevented [10]. The cardiovascular benefit outweighs the glycemic risk for nearly every eligible patient.

Lisinopril, on the other hand, may carry a neutral or mildly favorable metabolic profile. In the ALLHAT trial, the lisinopril group had slightly lower fasting glucose at 4 years compared to the chlorthalidone group, though chlorthalidone is known to worsen glucose metabolism [2]. ACE inhibitors have been associated with a modest reduction in new-onset diabetes in several observational analyses, possibly through improved insulin sensitivity via enhanced bradykinin activity. A 2006 Diabetes Care meta-analysis estimated a 14% risk reduction for new-onset diabetes with ACE inhibitors relative to placebo or other antihypertensives [11].

Renal and Electrolyte Considerations

Lisinopril can raise serum potassium. Hyperkalemia (potassium above 5.5 mEq/L) occurs in 2-6% of patients on ACE inhibitors, rising sharply in those with chronic kidney disease, diabetes, or concurrent potassium-sparing diuretics. ALLHAT reported higher rates of hyperkalemia in the lisinopril arm compared to chlorthalidone [2]. Routine monitoring of renal function and electrolytes is standard practice within the first 1-2 weeks of ACE inhibitor initiation or dose change, per the KDIGO 2021 Blood Pressure Guidelines [12].

ACE inhibitors also carry a risk of acute kidney injury (AKI) in patients with bilateral renal artery stenosis or significant volume depletion. Serum creatinine increases of up to 30% are acceptable upon initiation and do not warrant discontinuation, per the KDIGO recommendation.

Rosuvastatin has a minor renal signal: proteinuria was noted at higher doses (40 mg) in early trials, primarily tubular in origin and generally transient. The FDA label for Crestor recommends starting at 5 mg in patients with severe renal impairment (GFR <30 mL/min/1.73 m²) rather than the standard 10-20 mg [13]. Unlike lisinopril, rosuvastatin does not affect potassium homeostasis.

Hepatic Safety

All statins require liver function awareness, though the era of routine periodic liver enzyme testing has largely ended. The 2012 FDA safety communication removed the recommendation for routine liver enzyme monitoring, noting that serious liver injury with statins is rare and unpredictable, making periodic testing ineffective as a screen [14]. Clinicians now check baseline liver enzymes and repeat testing only if symptoms suggest hepatotoxicity (jaundice, malaise, unexplained fatigue).

In JUPITER, alanine aminotransferase (ALT) elevations above 3 times the upper limit of normal occurred in 1.2% of the rosuvastatin group vs. 1.0% on placebo [1]. That difference is clinically insignificant.

Lisinopril has a weaker hepatic signal. Rare case reports of cholestatic jaundice exist, but they are exceedingly uncommon and not a practical concern in routine prescribing.

Drug Interactions

Rosuvastatin's interaction profile is narrower than older statins like simvastatin because it is minimally metabolized by cytochrome P450 3A4. Still, concomitant use with cyclosporine, gemfibrozil, or certain protease inhibitors increases rosuvastatin exposure and myopathy risk. The FDA prescribing information mandates dose caps in these scenarios [13].

Lisinopril has fewer pharmacokinetic interactions because it is not metabolized, it is excreted unchanged by the kidneys. The primary concern is pharmacodynamic: concomitant NSAIDs blunt the antihypertensive effect and increase AKI risk, while potassium supplements or potassium-sparing diuretics compound hyperkalemia. The 2017 ACC/AHA Hypertension Guideline warns specifically against dual renin-angiotensin-aldosterone system blockade (ACE inhibitor plus ARB or direct renin inhibitor) due to increased renal and hyperkalemic events [15].

Who Tolerates Which Drug Better

Tolerability depends on the patient. A useful clinical heuristic:

Patients more likely to tolerate rosuvastatin well include those without a history of statin myalgia, those under 75, those not on interacting medications, and those with stable renal function.

Patients more likely to tolerate lisinopril well include men (lower cough incidence), non-East-Asian patients, those without a history of angioedema, and those without advanced chronic kidney disease (eGFR above 30).

The 2018 American College of Cardiology expert consensus on noncardiac surgery noted that statins and ACE inhibitors are among the most commonly held medications perioperatively, though the evidence for holding ACE inhibitors (due to intraoperative hypotension) is stronger than for holding statins [16].

Dr. Steven Nissen, Chief Academic Officer of the Heart, Vascular, and Thoracic Institute at the Cleveland Clinic, stated in a 2023 ACC presentation: "The biggest side effect of a statin is not taking it. Myalgia concerns lead to discontinuation rates that far exceed the actual pharmacologic muscle toxicity of these drugs."

The American Heart Association's 2018 cholesterol guideline reinforced this perspective. According to the AHA/ACC Multisociety Guideline on Blood Cholesterol Management: "Clinicians should reassess and counsel patients who report statin-associated side effects before discontinuing therapy, including a trial of an alternative statin or dosing regimen" [17].

Discontinuation Rates and Real-World Adherence

Real-world adherence differs markedly from trial settings. A 2019 JAMA Cardiology analysis of over 24,000 patients found that approximately 13.2% of statin users discontinued within the first year, with muscle symptoms cited most frequently [18]. For ACE inhibitors, a European Heart Journal study reported 1-year persistence rates around 70-75%, with cough as the leading reason for switching, most often to an ARB [19].

Both drug classes perform significantly better when patients receive anticipatory counseling about expected side effects. Telling a patient "you may notice mild muscle soreness that usually resolves in the first few weeks" or "a dry cough could develop; it is the drug, not an infection" reduces unnecessary discontinuation.

Head-to-Head Safety Summary

No trial has randomized patients to rosuvastatin vs. lisinopril, and one likely never will. They treat different targets. Cross-trial comparisons carry inherent limitations: JUPITER enrolled a relatively healthy, inflammation-elevated population while ALLHAT enrolled high-risk hypertensive patients with at least one additional cardiovascular risk factor. Patient demographics, follow-up durations (1.9 years vs. 4.9 years), and endpoint definitions differed.

What the data do support: rosuvastatin's primary tolerability burden is musculoskeletal, with a secondary metabolic signal around diabetes. Lisinopril's primary tolerability burden is respiratory (cough), with secondary concerns around hyperkalemia and the rare but serious risk of angioedema. Both drugs have extensive post-marketing safety records spanning decades, and both remain first-line agents in their respective classes.

For patients taking both medications who develop a new symptom, the clinical approach is straightforward: match the symptom to the known adverse-effect profile, hold the suspected agent, observe, and re-challenge if appropriate. Muscle pain points toward rosuvastatin. A dry cough points toward lisinopril. Facial swelling mandates permanent ACE inhibitor discontinuation.